🇺🇸 FDA
Patent

US 10253294

Galactose oxidase treatment of dendritic cells to improve their immunogenicity

granted A61KA61K2239/31A61K40/19

Quick answer

US patent 10253294 (Galactose oxidase treatment of dendritic cells to improve their immunogenicity) held by Julius-Maximilians-Universitat Wurzburg expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Julius-Maximilians-Universitat Wurzburg
Grant date
Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K2239/31, A61K40/19, A61K40/24, A61K40/42